Entered into an exclusive license agreement with Italfarmaco for the Duchenne Muscular Dystrophy treatment Givinostat in Japan, initiating a strategic partnership in rare disease therapeutics.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4552-20260123-01.pdf","jir_short_summary":"Entered into an exclusive license agreement with Italfarmaco for the Duchenne Muscular Dystrophy treatment Givinostat in Japan, initiating a strategic partnership in rare disease therapeutics.","jir_summary":"### Overview of the Agreement\nJCR Pharmaceuticals Co., Ltd. has entered into an exclusive license agreement with Italfarmaco for the Duchenne Muscular Dystrophy (DMD) treatment Givinostat in Japan. This expands the rare disease treatment portfolio and promotes the joint exploration of opportunities in R&D pipelines and core technologies of both companies. Givinostat is a histone deacetylase (HDAC) inhibitor and is expected to be a non-steroidal treatment for DMD.\n\n### Current Status and Future Outlook of the Treatment\nGivinostat was approved in the US in March 2024 and received conditional approval in the EU in June 2025, but it is not yet approved in Japan. The domestic DMD patient population is approximately 3,500, with an estimated over 1,000 patients aged six and older who are ambulatory, indicating significant commercial potential. The goal is to obtain marketing authorization by 2028, with Phase III clinical trials (EPIDYS Study) currently underway.","jir_financial_highlights":"Contract Details: Exclusive license agreement for Duchenne Muscular Dystrophy treatment Givinostat in Japan (New Contract)\nNumber of Patients: Approximately 3,500 domestically (Unknown)\nRegulatory Approval Status: US approval March 2024, EU conditional approval June 2025, not yet approved in Japan (Unknown)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #M&A, #RareDiseaseTherapeutics","jir_key_figures":"Domestic DMD Patient Population: Approximately 3,500\nGivinostat US Approval: March 2024\nGivinostat EU Conditional Approval: June 2025","jir_meta_title":"JCR Pharmaceuticals Signs Exclusive License Agreement with Italfarmaco for DMD Treatment Givinostat in Japan","jir_meta_description":"JCR Pharmaceuticals has concluded an exclusive license agreement with Italfarmaco for the Duchenne Muscular Dystrophy treatment Givinostat in Japan. The domestic patient population is approximately 3,500, aiming for approval by 2028.","jir_og_title":"JCR Pharmaceuticals Announces Agreement for DMD Treatment with Italfarmaco","jir_og_description":"Exclusive license agreement for rare disease therapeutic Givinostat in Japan. Approximately 3,500 domestic patients, advancing clinical development towards regulatory approval.","jir_og_image_url":"\/assets\/og\/company-m_and_a_alliance.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-20578","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n